Vaccine Therapy in Treating Patients With Metastatic Melanoma
Public ClinicalTrials.gov record NCT00003792. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.
Study identification
- NCT ID
- NCT00003792
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- MART-1 antigen Biological
- filgrastim Biological
- flu matrix peptide p58-66 Biological
- gp100 antigen Biological
- recombinant MAGE-3.1 antigen Biological
- tyrosinase peptide Biological
- in vitro-treated peripheral blood stem cell transplantation Procedure
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 1999
- Primary completion
- Not listed
- Completion
- Sep 30, 2006
- Last update posted
- Jun 25, 2013
1999 – 2006
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Melanoma (Skin) trials
Other public records listing Melanoma (Skin). Sorted by last update posted; newest first. Not a recommendation.
- NCT05279027: Zr89 + PET Companion Trial Active, not recruiting
- NCT06400550: Identification of Metabolic Phenotypes Associated With Melanoma Metastasis Recruiting
- NCT05704647: Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases Recruiting
- NCT07527325: Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Not yet recruiting
- NCT06298734: High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial Recruiting
- NCT06771544: Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003792, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2013 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003792 live on ClinicalTrials.gov.